Metsera (NASDAQ:MTSR) Shares Up 7.6% – Time to Buy?

Metsera, Inc. (NASDAQ:MTSR)’s stock price shot up 7.6% on Monday . The stock traded as high as $28.28 and last traded at $27.12. 40,441 shares traded hands during trading, a decline of 93% from the average session volume of 557,944 shares. The stock had previously closed at $25.21.

Analyst Upgrades and Downgrades

A number of research analysts have commented on MTSR shares. Cantor Fitzgerald initiated coverage on Metsera in a report on Tuesday, February 25th. They issued an “overweight” rating on the stock. Guggenheim began coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price target on the stock. Bank of America initiated coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price objective for the company. Finally, Evercore ISI started coverage on shares of Metsera in a report on Tuesday, February 25th. They issued an “outperform” rating for the company.

Metsera Trading Up 11.7 %

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.